Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA guides on how AA can be converted to full approval.

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Mar 24, 2023 5:02pm

170 Views

Post# 35359561

RE:RE:RE:RE:RE:FDA guides on how AA can be converted to full approval.

I guess we shall see soon enough on the trial size as we can guess all we want but not up to us.
Personally I would just like to see one or both of our phase 3 trials up and running this year.
Now that would be a welcome early Xmas gift for all.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Jan. 10, 2025)